连续FSH给药双次取卵能否增加低反应者的成熟卵母细胞数?一项开放标签随机对照试验
本研究为单中心开放标签优势设计随机对照试验,纳入48例低卵巢储备患者,比较常规卵巢刺激与连续双重刺激双次取卵对MII卵母细胞总数的影响。结果显示两组累积MII卵母细胞数无显著差异,连续刺激组第二次刺激取消率达39.1%。
要点
- 连续双重刺激组与常规刺激组的累积MII卵母细胞数无显著差异。
- 连续刺激组因第二次刺激反应不足的取消率为39.1%(9/23)。
- 第一次取卵后,hCG触发组的COC数和MII卵母细胞数均显著高于GnRH激动剂触发组。
核心结论
- 与一次常规卵巢刺激相比,连续双重刺激双次取卵并未增加低反应者的累积MII卵母细胞总数。
研究设计与样本
- 开放标签、优势设计随机对照试验,单中心三级中心进行,2019年10月至2021年9月按1:1随机分组。
- 纳入25至40岁、抗苗勒管激素≤1.5 ng/ml、窦卵泡计数≤6或既往刺激后获卵≤5枚的患者。
- 70例符合初筛,48例满足最终纳入标准并随机,脱落后A组23例、B组23例。
主要发现
- 累积COC数A组5.3±2.7 vs B组5.3±3.0(P=0.95),累积MII卵母细胞数A组4.1±2.4 vs B组4.3±2.7(P=0.77)。
- 第3天优质和良好胚胎数A组3.0±2.0 vs B组2.7±2.0(P=0.63)。
- 第一次取卵后COC数A组5.3±2.7 vs B组3.3±2.2,差值95%CI(0.54至3.45),P=0.004。
- 第一次取卵后MII卵母细胞数A组4.1±2.4 vs B组3.0±2.2,差值95%CI(-0.15至2.6),P=0.05。
- 第3天优质和良好胚胎数A组3.0±2.0 vs B组1.9±1.7,P=0.02。
临床怎么用
- 研究方案中,A组采用hCG触发排卵,34-36小时后取卵,行第3/5天新鲜单胚胎或双胚胎移植。
- 研究方案中,B组采用GnRH激动剂触发排卵,不间断FSH进行第二次刺激,当存在≥17 mm卵泡时以hCG完成第二次刺激,两次取卵均采用全胚冷冻策略,后续在人工准备的冻融周期中移植一或两个胚胎。
- 研究方案中,第二次刺激额外13天后若无≥17 mm卵泡则取消第二周期。
- 所有取卵由对第一次治疗设盲的资深生育专家执行,按常规临床实践抽吸所有>10 mm卵泡。
局限性
- 本研究把握度设计用于证明双重刺激后MII卵母细胞数的优势。
- 研究双重刺激对妊娠率的影响需要更大的样本量。
- 胚胎玻璃化冷冻和移植政策的异质性妨碍了两组胚胎学结果的正确比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is there an increase in the total number of metaphase II (MII) oocytes between a conventional ovarian stimulation (OS) and a double uninterrupted stimulation? SUMMARY ANSWER: There is no increase in the total number of MII oocytes when comparing one conventional OS to a continuous stimulation with double oocyte aspiration. WHAT IS KNOWN ALREADY: Based on the concept of multiple follicular waves, the combination of two stimulations in the same ovarian cycle has gained interest in patients with a low ovarian reserve. This so-called dual stimulation approach is usually characterized by a discontinuation of FSH administration for ∼5 days and appears to have a favourable impact on the number of retrieved oocytes without affecting the embryo quality or ploidy status. The outcomes of dual uninterrupted OS have not yet been studied. STUDY DESIGN, SIZE, DURATION: This was an open-label randomized controlled trial (RCT) with superiority design, performed in a single tertiary centre. Subjects were randomized with a 1:1 allocation into two groups between October 2019 and September 2021. All patients underwent a conventional stimulation with recombinant FSH. When two or more follicles of 17 mm were present, the final inclusion criterion was assessed; randomization occurred only in the presence of ≤9 follicles of ≥11 mm. In Group A, ovulation was triggered with hCG, and oocyte retrieval (OR) was performed 34-36 h later, followed by a fresh single or double embryo transfer (SET or DET) on Day 3/5. In Group B, ovulation was triggered with GnRH agonist, followed by another OS, without discontinuation of the FSH administration. In the presence of one or more follicles of ≥17 mm, the second stimulation was completed with hCG. A freeze-all strategy (Day 3/5) was applied for both retrievals, followed by transfer of one or two embryos in an artificially prepared frozen-thawed cycle. In the absence of one or more follicles of ≥17 mm after 13 additional days of stimulation, the second cycle was cancelled. All ORs were executed by a senior fertility specialist who was blinded for the first treatment, and all follicles >10 mm were aspirated, according to routine clinical practice. The primary outcome was the total number of MII oocytes. Patients were followed up until all embryos were transferred, or until live birth was achieved. Other secondary outcomes included the number of cumulus-oocyte complexes (COCs), the number of good quality embryos (Day 3/5), the ongoing pregnancy rate, and gonadotropin consumption. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients between 25 and 40 years old, with an anti-Müllerian hormone level of ≤1.5 ng/ml, antral follicle count of ≤6, or ≤5 oocytes after a previous stimulation, were included. At the start, 70 patients were eligible for participation in the trial, of whom 48 patients fulfilled the final inclusion criterium and were randomized. After drop-out of two patients, 23 patients were randomized to a single round of OS (Group A), and 23 patients were randomized to two uninterrupted rounds of OS (Group B). MAIN RESULTS AND THE ROLE OF CHANCE: Baseline characteristics were similar between both groups. The cumulative number of COCs and MII oocytes after completion of the second OR was similar in Group A and Group B [5.3 ± 2.7 versus 5.3 ± 3.0 (P = 0.95); 4.1 ± 2.4 versus 4.3 ± 2.7 (P = 0.77)]. Likewise, a comparable number of excellent and good quality embryos was available on Day 3 (3.0 ± 2.0 versus 2.7 ± 2.0; P = 0.63). In Group B, the cancellation rate due to insufficient response to the second round of stimulation was 39.1% (9/23). When focusing on the first stimulation in both groups, there were no significant differences regarding basal FSH, gonadotropin consumption, and the number of preovulatory follicles. After the first OR, the mean number of COC and MII oocytes was significantly higher in Group A (who had hCG triggering), compared to Group B (who had GnRH agonist triggering) [5.3 ± 2.7 versus 3.3 ± 2.2; difference 95% CI (0.54 to 3.45), P = 0.004 and 4.1 ± 2.4 versus 3.0 ± 2.2; difference 95% CI (-0.15 to 2.6), P = 0.05, respectively]. Likewise, the number of excellent and good quality embryos on Day 3 was significantly higher (3.0 ± 2.0 versus 1.9 ± 1.7; P = 0.02) in Group A. LIMITATIONS, REASONS FOR CAUTION: This study was powered to demonstrate superiority for the number of MII oocytes after dual stimulation. Investigating the impact of dual stimulation on pregnancy rates would have required a larger sample size. Furthermore, the heterogeneity in embryo vitrification and transfer policies precluded a correct comparison of embryologic outcomes between both groups. WIDER IMPLICATIONS OF THE FINDINGS: This is the first RCT investigating the role of continuous stimulation with double aspiration in low responders. Our results show no statistically significant differences in the cumulative number of MII oocytes between one conventional stimulation with fresh ET and two consecutive stimulations with a freeze-only approach. Furthermore, the observed suboptimal oocyte yield after agonist ovulation triggering in low responders in the dual uninterrupted OS group is a reason for concern and further scrutiny, given that previous RCTs have shown similar outcomes in normal and high responders after hCG and GnRH agonist triggers. STUDY FUNDING/COMPETING INTEREST(S): This work was supported in part by a research grant from Organon. H.T. received honoraria for lectures and presentations from Abbott, Cooper Surgical, Gedeon-Richter, Cook, Goodlife, and Ferring. L.B. received fees for lectures from Merck & Organon and support for attending ESHRE 2023. M.D.V. reports fees for lectures from Ferring, Merck, Organon, IBSA, Gedeon Richter, and Cooper Surgical and support for attending ASRM 2023. S.M. received honoraria for lectures and presentations from Abbott, Cooper Surgical, Gedeon-Richter, IBSA, and Merck. C.B. was on the Advisory board and received consulting fees from Theramex and received honoraria for lectures and presentations from Abbott, Ferring, Gedeon-Richter, IBSA, and Merck. TRIAL REGISTRATION NUMBER: NCT03846544. TRIAL REGISTRATION DATE: 19 February 2019. DATE OF FIRST PATIENT’S ENROLMENT: 28 October 2019.
引用
- Boudry L, Mateizel I, Wouters K, et al. Does dual oocyte retrieval with continuous FSH administration increase the number of mature oocytes in low responders? An open-label randomized controlled trial. Hum Reprod. 2024. PMID: 38199789. doi:10.1093/humrep/dead276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。